May 2006
Volume 47, Issue 13
Free
ARVO Annual Meeting Abstract  |   May 2006
Angniotension II Type 1 Receptor–Mediated Inflammation Is Required for Choroidal Neovascularization
Author Affiliations & Notes
  • N. Nagai
    Keio University School of Medicine, Laboratory of Retinal Cell Biology, Department of Ophthalmology, Tokyo, Japan
    Keio University School of Medicine, Department of Cell Differentiation, Tokyo, Japan
  • Y. Oike
    Keio University School of Medicine, Laboratory of Retinal Cell Biology, Department of Cell Diffferentiation, Tokyo, Japan
  • K. Izumi
    Keio University School of Medicine, Laboratory of Retinal Cell Biology, Department of Ophthalmology, Tokyo, Japan
  • T. Urano
    Keio University School of Medicine, Laboratory of Retinal Cell Biology, Department of Cell Diffferentiation, Tokyo, Japan
  • Y. Kubota
    Keio University School of Medicine, Department of Cell Differentiation, Tokyo, Japan
  • Y. Ozawa
    Keio University School of Medicine, Laboratory of Retinal Cell Biology, Department of Ophthalmology, Tokyo, Japan
  • M. Inoue
    Keio University School of Medicine, Department of Ophthalmology, Tokyo, Japan
  • K. Tsubota
    Keio University School of Medicine, Department of Ophthalmology, Tokyo, Japan
  • T. Suda
    Keio University School of Medicine, Department of Cell Differentiation, Tokyo, Japan
  • S. Ishida
    Keio University School of Medicine, Laboratory of Retinal Cell Biology, Department of Ophthalmology, Tokyo, Japan
  • Footnotes
    Commercial Relationships  N. Nagai, Boehringer Ingelheim, F; Y. Oike, None; K. Izumi, None; T. Urano, None; Y. Kubota, None; Y. Ozawa, None; M. Inoue, None; K. Tsubota, None; T. Suda, None; S. Ishida, Boehringer Ingelheim, F.
  • Footnotes
    Support  Grants–in–aid for scientific research of Japanese Ministry of Education, Culture, Sports, Science and Technology (No. 17791255)
Investigative Ophthalmology & Visual Science May 2006, Vol.47, 903. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      N. Nagai, Y. Oike, K. Izumi, T. Urano, Y. Kubota, Y. Ozawa, M. Inoue, K. Tsubota, T. Suda, S. Ishida; Angniotension II Type 1 Receptor–Mediated Inflammation Is Required for Choroidal Neovascularization . Invest. Ophthalmol. Vis. Sci. 2006;47(13):903.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: : To investigate the role of the rein–angiotensin system (RAS) in the development of choroidal neovasculariztion (CNV).

Methods: : Laser photocoagulation was used to induce CNV in C57BL/6 mice. Tissue localization of angiotensin II type 1 receptor (AT1–R) in CNV tissues of laser–treated mice and of patients with age–related macular degeneration (AMD) was analyzed by immunohistochemistry. mRNA and protein levels of AT1–R and AT2–R in the choroid of laser–treated mice were examined by RT–PCR and western blot analyses, respectively. An AT1–R blocker (ARB, telmisartan or valsartan) or an AT2–R blocker was administered daily for 1 week before and after the photocoagulation. One week after the photocoagulation, CNV volume was evaluated by volumetric measurements. Macrophages infiltrating to murine CNV were identified by immunostainig for F4/80. Choroidal mRNA and protein levels of vascular endothelial growth factor (VEGF), VEGF receptor (VEGFR)–1, VEGFR–2, intercellular adhesion molecule (ICAM)–1, monocyte chemotactic protein (MCP)–1 and interleukin (IL)–6 were examined by RT–PCR and ELISA, respectively.

Results: : AT1–R immunoreactivity was detected in vascular endothelial cells and infiltrating macrophages in human and murine CNV tissues. Induction of CNV led to an increase in choroidal mRNA and protein levels of AT1–R, but not AT2–R. CNV volume was significantly suppressed by the treatment with an AT1–R blocker (telmisartan or valsartan), but not with an AT2–R blocker. AT1–R blockade by telmisartan significantly suppressed macrophage infiltration and choroidal VEGFR–1, ICAM–1, MCP–1 and IL–6 levels compared to the vehicle treatment.

Conclusions: : AT1–R signaling blockade inhibited various inflammatory processes such as choroidal ICAM–1, MCP–1 and IL–6 upregulation and macrophage infiltration, resulting in the suppression of CNV. The present data indicate the possibility of AT1–R blockade as a novel therapeutic strategy to inhibit CNV associated with AMD.

Keywords: choroid: neovascularization • inflammation • drug toxicity/drug effects 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×